Entecavir for Chronic Hepatitis B

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary aim of this study is to asses the efficacy (both virological and clinical) and safety of ETV in both NA-naïve and NA-experienced chronic hepatitis B patients, and to explore baseline factors associated with virologic reponse (VR) to ETV.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Foundation for Liver Research
• Treatments: Entecavir

Criteria

Inclusion Criteria:

• HBsAg positive for at least 6 months

• Entecavir therapy for at least 3 months

Exclusion Criteria:

• viral co infections

• concomitant antiviral therapy